Author/Editor		Wouden, Cathelijne H.; Cambon-Thomsen, Anne; Cecchin, Erika; Cheung, Ka-Chun; Dávila-Fajardo, Cristina Lucía; Deneer, Vera H.; Dolžan, Vita; Ingelman-Sundberg, Magnus; Jönsson, Siv; Karlsson, Mats O.; Klen, Jasna; Mlinšek, Gregor; Poplas-Susič, Tonka
Title		Implementing pharmacogenomics in Europe
Type		članek
Vol. and No.		Letnik 101, št. 3
Publication year		2017
Volume		str. 341-358
ISSN		0009-9236 - Clinical pharmacology and therapeutics
Language		eng
Abstract		Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programmes have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual drug-gene pairs. The Ubiquitous Pharmacogenomics Consortium (U-PGx), which has been funded by the European Commission's Horizon-2020 programme, aims to address this unmet need. In a prospective, block-randomized, controlled clinical study (PREPARE), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its multi-center, multi-gene, multi-drug, multi-ethnic, and multi-healthcare system approach. This article is protected by copyright. All rights reserved.
Keywords		adverse drug reactions clinical trial genotyping neželeni učinki zdravil klinično preizkušanje genotipizacija